SeneXta Therapeutics was initially founded to acquire intellectual properties related to the treatment of Alzheimer's disease (AD) and stroke (SNX-001).
SeneXta develops its pipeline using a virtual model made of international scientific experts, clinicians, CNS opinion leaders and well-known service providers (CROs and CMOs).
The company has established solid collaborations with US and European Universities. These alliances allow SeneXta to utilize R&D capacity of large institutions for the development of new compounds.
SeneXta is focused on products that are in advanced clinical stage of development and have higher probability of success.
SeneXta has already secured capital to complete IND for first product (SNX-001).
Download Senexta Brochure